Subtopic Deep Dive

← Eicosanoids and Hypertension Pharmacology

Soluble Epoxide Hydrolase Inhibition Therapy
Research Guide

What is Soluble Epoxide Hydrolase Inhibition Therapy?

Soluble epoxide hydrolase (sEH) inhibition therapy targets the enzyme that metabolizes epoxyeicosatrienoic acids (EETs) to increase EET bioavailability for antihypertensive and anti-inflammatory effects.

sEH hydrolyzes EETs, cytochrome P450-derived arachidonic acid metabolites that promote vasodilation and reduce inflammation. Inhibitors block this hydrolysis, elevating EET levels to treat hypertension and renal diseases. Over 200 papers explore sEH inhibitors, with foundational work by Imig (2005) cited 232 times.

Curated Papers

Key Challenges

Why It Matters

sEH inhibition offers cardioprotective benefits by enhancing EET-mediated vascular relaxation and reducing blood pressure in hypertension models (Imig, 2005). Clinical potential includes anti-inflammatory effects in cardiovascular diseases, as EETs counterbalance pro-inflammatory prostaglandins (Ricciotti and FitzGerald, 2011). Imig (2005) highlights renal disease applications where EET elevation improves blood flow regulation. Panigrahy et al. (2011) note EETs' role in vascular tone, supporting sEH inhibitors as drugs with minimal side effects.

Key Research Challenges

sEH Inhibitor Selectivity

Designing inhibitors specific to sEH avoids off-target effects on other hydrolases. Decker et al. (2009) detail mammalian epoxide hydrolases' roles in xenobiotic metabolism, complicating selectivity. Achieving high potency without toxicity remains critical for clinical translation.

EET Biomarker Monitoring

Quantifying diol metabolites from EET hydrolysis requires sensitive assays for therapy efficacy. Imig (2005) emphasizes tracking EET/diol ratios in renal diseases. Variability in patient metabolism hinders reliable biomarkers.

Clinical Translation Barriers

Moving sEH inhibitors from preclinical hypertension models to human trials faces pharmacokinetic challenges. Panigrahy et al. (2011) show EETs regulate vascular tone, but long-term safety data is limited. Inflammation modulation in complex diseases like hypertension needs validation (Ricciotti and FitzGerald, 2011).

Essential Papers

Prostaglandins and Inflammation

Emanuela Ricciotti, Garret A. FitzGerald · 2011 · Arteriosclerosis Thrombosis and Vascular Biology · 3.6K citations

Prostaglandins are lipid autacoids derived from arachidonic acid. They both sustain homeostatic functions and mediate pathogenic mechanisms, including the inflammatory response. They are generated ...

Eicosanoid storm in infection and inflammation

Edward A. Dennis, Paul C. Norris · 2015 · Nature reviews. Immunology · 1.4K citations

Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets

Bei Wang, Lujin Wu, Jing Chen et al. · 2021 · Signal Transduction and Targeted Therapy · 1.2K citations

Significance of long chain polyunsaturated fatty acids in human health

Rafael Zárate, Nabil el Jaber-Vazdekis, Noemı́ Tejera et al. · 2017 · Clinical and Translational Medicine · 534 citations

Abstract In the last decades, the development of new technologies applied to lipidomics has revitalized the analysis of lipid profile alterations and the understanding of the underlying molecular m...

Arachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases

Thomas Sonnweber, Alex Pizzini, Manfred Nairz et al. · 2018 · International Journal of Molecular Sciences · 420 citations

Lipid and immune pathways are crucial in the pathophysiology of metabolic and cardiovascular disease. Arachidonic acid (AA) and its derivatives link nutrient metabolism to immunity and inflammation...

(n-3) Fatty Acids and Cardiovascular Health: Are Effects of EPA and DHA Shared or Complementary?

Dariush Mozaffarian, Jason Wu · 2012 · Journal of Nutrition · 359 citations

Cardioprotective mechanism of omega-3 polyunsaturated fatty acids

Jin Endo, Makoto Arita · 2015 · Journal of Cardiology · 352 citations

Reading Guide

Foundational Papers

Start with Imig (2005) for sEH-EET basics in renal hypertension (232 citations), then Ricciotti and FitzGerald (2011, 3607 citations) for eicosanoid inflammation context, and Panigrahy et al. (2011, 287 citations) for EET vascular mechanisms.

Recent Advances

Wang et al. (2021, 1243 citations) on arachidonic pathways; Brennan et al. (2021, 242 citations) on pro-resolving mediators linking to sEH therapy.

Core Methods

EET quantification via LC-MS; sEH assays measure diol production. Inhibitor design uses structural biology (Decker et al., 2009); preclinical hypertension models test blood pressure reduction (Imig, 2005).

How PapersFlow Helps You Research Soluble Epoxide Hydrolase Inhibition Therapy

Discover & Search

Research Agent uses searchPapers('soluble epoxide hydrolase inhibitors hypertension') to find Imig (2005), then citationGraph reveals 232 citing papers on renal EET therapy, and findSimilarPapers expands to Wang et al. (2021) on arachidonic pathways.

Analyze & Verify

Analysis Agent applies readPaperContent on Imig (2005) to extract EET mechanisms, verifies claims with CoVe against Panigrahy et al. (2011), and runs PythonAnalysis to plot EET/diol ratios from extracted data using pandas, with GRADE scoring evidence strength for hypertension claims.

Synthesize & Write

Synthesis Agent detects gaps in clinical sEH inhibitor trials via contradiction flagging between Imig (2005) and recent reviews, then Writing Agent uses latexEditText for methods sections, latexSyncCitations for Ricciotti (2011), and latexCompile for full reports with exportMermaid diagrams of EET pathways.

Use Cases

"Analyze EET/diol ratios in sEH inhibition datasets from hypertension studies."

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib plots diol trends from Imig 2005 data) → researcher gets statistical visualizations of metabolite changes.

"Draft LaTeX review on sEH inhibitors for hypertension pharmacology."

Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Imig 2005, Panigrahy 2011) + latexCompile → researcher gets compiled PDF with cited EET pathways.

"Find code for modeling sEH inhibitor binding in EET metabolism."

Research Agent → paperExtractUrls (Wang 2021) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts for arachidonic acid simulations.

Automated Workflows

Deep Research workflow scans 50+ papers on sEH inhibition (searchPapers → citationGraph → DeepScan checkpoints), producing structured reports on EET bioavailability in hypertension. Theorizer generates hypotheses on sEH-EET-prostaglandin interactions from Ricciotti (2011) and Imig (2005). DeepScan verifies biomarker claims with CoVe across Dennis (2015) and Panigrahy (2011).

Try Doxa for Soluble Epoxide Hydrolase Inhibition Therapy Research

Frequently Asked Questions

What is soluble epoxide hydrolase inhibition therapy?

It blocks sEH enzyme to prevent EET hydrolysis, raising EET levels for vasodilation and anti-hypertension effects (Imig, 2005).

What methods develop sEH inhibitors?

Screening targets sEH active site; assays measure EET/diol ratios. Decker et al. (2009) describe hydrolase structures for rational design.

What are key papers on sEH inhibition?

Imig (2005, 232 citations) on renal targets; Panigrahy et al. (2011, 287 citations) on EET vascular roles.

What open problems exist in sEH therapy?

Clinical trials lack long-term data; biomarker standardization for diols needed (Imig, 2005). Selectivity over other hydrolases persists (Decker et al., 2009).